Prelude Capital Management’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Prelude Capital Management’s Portfolio NTGN Stock Details NTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-119	Closed	–	–	2400
2019 Q3	$0	Sell	119 -14	-11%	-$43	﹤0.01%	2249
2019 Q2	$1K	Sell	133 -9	-6%	-$50	﹤0.01%	1602
2019 Q1	$1K	Buy	+142	New	+$743	﹤0.01%	1714
2018 Q4	–	Sell	-1,642	Closed	-$14K	–	2333
2018 Q3	$14K	Buy	+1,642	New	+$18.2K	﹤0.01%	1397

Other funds holding NTGN

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's NTGN Position: Q4 2019 in Review

Prelude Capital Management sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q4 2019, closing a stake of 119 shares.

Prelude Capital Management first reported a position in NTGN in Q3 2018 and held it in 4 quarters. The position peaked at $14K in Q3 2018. 46 funds tracked by Wall St. Rank hold NTGN as of Q4 2019.

Prelude Capital Management reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Prelude Capital Management sold 119 Neon Therapeutics, Inc. Common Stock shares in Q4 2019.
Prelude Capital Management first reported a position in Neon Therapeutics, Inc. Common Stock in Q3 2018 and held it in 4 quarters.
Prelude Capital Management's Neon Therapeutics, Inc. Common Stock position peaked at $14K in Q3 2018.
46 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Prelude Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.